Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.

Allott EH, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ.

Cancer Prev Res (Phila). 2017 Jun;10(6):319-326. doi: 10.1158/1940-6207.CAPR-17-0019. Epub 2017 May 9.

PMID:
28487295
2.

Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.

Cui K, Li X, Du Y, Tang X, Arai S, Geng Y, Xi Y, Xu H, Zhou Y, Ma W, Zhang T.

Oncotarget. 2017 May 30;8(22):36674-36684. doi: 10.18632/oncotarget.16230.

3.

Fatty Acid Synthesis Intermediates Represent Novel Noninvasive Biomarkers of Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.

Singh KB, Singh SV.

Cancer Prev Res (Phila). 2017 May;10(5):279-289. doi: 10.1158/1940-6207.CAPR-17-0001. Epub 2017 Mar 14.

PMID:
28292742
4.

Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice.

Ni X, Yu H, Wang S, Zhang C, Shen S.

Mar Drugs. 2017 Mar 8;15(3). pii: E66. doi: 10.3390/md15030066.

5.

Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.

Shin YS, Lee JW, Kim MK, Jeong YB, Park SC.

Investig Clin Urol. 2017 Mar;58(2):98-102. doi: 10.4111/icu.2017.58.2.98. Epub 2017 Feb 15.

6.

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome.

Fertig R, Shapiro J, Bergfeld W, Tosti A.

Skin Appendage Disord. 2017 Jan;2(3-4):120-129. doi: 10.1159/000450617. Epub 2016 Sep 23. Review.

7.

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS.

Clin Epidemiol. 2017 Feb 10;9:83-91. doi: 10.2147/CLEP.S124674. eCollection 2017.

8.

Cancer in the Medically Underserved Population.

Olaku OO, Taylor EA.

Prim Care. 2017 Mar;44(1):87-97. doi: 10.1016/j.pop.2016.09.020. Review.

PMID:
28164822
9.

Cancer Prevention: Lessons Learned and Future Directions.

Dunn BK, Kramer BS.

Trends Cancer. 2016 Dec;2(12):713-722. doi: 10.1016/j.trecan.2016.11.003.

PMID:
28138568
10.

Vitamin K epoxide reductase regulation of androgen receptor activity.

Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO.

Oncotarget. 2017 Feb 21;8(8):13818-13831. doi: 10.18632/oncotarget.14639.

11.

Unusual Cushing's Syndrome and Hypercalcitoninaemia due to a Small Cell Prostate Carcinoma.

Balestrieri A, Magnani E, Nuzzo F.

Case Rep Endocrinol. 2016;2016:6308058. doi: 10.1155/2016/6308058. Epub 2016 Dec 1.

12.

Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study.

Wang Y, Wang X, Yu J, Ouyang J, Shen W, Zhou Y, Hou J, Wen D, Pu J, Shan Y, Xue B.

J Res Med Sci. 2016 Sep 1;21:79. eCollection 2016.

13.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

PMID:
27683182
14.

Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS.

J Clin Aesthet Dermatol. 2016 Jul;9(7):56-62. Epub 2016 Jul 1. Review.

15.

New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives.

Albisinni S, Biaou I, Marcelis Q, Aoun F, De Nunzio C, Roumeguère T.

BMC Urol. 2016 Sep 15;16(1):58. doi: 10.1186/s12894-016-0176-0. Review.

16.

The association between sexual function and prostate cancer risk in US veterans.

Zapata DF, Howard LE, Frank J, Simon RM, Hoyo C, Grant DJ, Freedland SJ, Vidal AC.

Asian J Androl. 2017 Mar-Apr;19(2):191-195. doi: 10.4103/1008-682X.184869.

17.

Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model.

Suman S, Das TP, Moselhy J, Pal D, Kolluru V, Alatassi H, Ankem MK, Damodaran C.

Oncotarget. 2016 Aug 16;7(33):53751-53761. doi: 10.18632/oncotarget.10733.

18.

The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels.

Jayalath VH, Ireland C, Fleshner NE, Hamilton RJ, Jenkins DJ.

Prostate. 2016 Nov;76(15):1445-53. doi: 10.1002/pros.23228. Epub 2016 Jul 12.

19.

The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey.

Huang WT, Erickson SR, Hansen RA, Wu CH.

Medicine (Baltimore). 2016 Jun;95(25):e3909. doi: 10.1097/MD.0000000000003909.

20.

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.

Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, Smits GA, Vergunst H, Mulders PF.

Springerplus. 2016 May 17;5:653. doi: 10.1186/s40064-016-2280-8. eCollection 2016.

Supplemental Content

Support Center